GENEO Capital Entrepreneur

GENEO's 'entreprise à mission' designation means the firm's social-purpose objectives are written into its legal charter and independently verified. This forces the investment committee to assess potential deals against both financial and impact milestones. The structure also aligns management compensation with ESG outcomes, not just carried interest, making the investment process more deliberate in its screening for mission-aligned portfolio companies.

GENEO focuses on European growth-stage opportunities, typically deploying equity tickets of €5M to €30M. The firm has historically targeted companies with €5M to €50M in revenue and can structure both minority and majority positions. Its mandate spans digital health, enterprise software, and fintech, with a geographic emphasis on France and the Benelux region.

Investment decisions at GENEO are led by co-founders Xavier Lazarus and Marc Bonnamour, alongside partners Benoît Lajudie and Kevin Benhaddouch. The firm operates with a centralized investment committee that evaluates deals through both financial return and impact criteria, consistent with its 'entreprise à mission' obligations.

GENEO is an independent asset manager, not a family office. It was founded as a third-party fund manager raising capital from institutional investors, including the European Investment Fund, rather than managing the wealth of a single family. Its structure is that of a French private equity management company operating growth funds.

GENEO has not publicly disclosed a formal co-investment program for outside GPs or LPs. Its primary deal structure involves direct equity investments from committed fund capital, and there is no public record of a dedicated co-investment vehicle or syndication club. The firm's low public profile limits detailed visibility into its post-investment governance practices.